# Development of human B-lymphocyte targeted bi-specific DART<sup>®</sup> molecules for the treatment of autoimmune disorders



- pose safety concerns in patients with autoimmune diseases, such as increased factor.
- autoimmune diseases by exploiting intrinsic inhibitory pathways.
- desirable to support optimal therapeutic dosing.
- was developed and systematically characterized both in vitro and in vivo including in a non-human primate for its bioactivity, safety, pharmacokinetics, and pharmacodynamic properties.





Wei Chen, Jeffrey Nordstrom, Steve Burke, Kalpana Shah, Valentina Ciccarone, Haiquan Li, Tim Hotaling, Jonathan Li, Sergey Gorlatov, Hua Li, Ralph Alderson, Scott Koenig, Ezio Bonvini, Syd Johnson, Paul Moore

MacroGenics, Inc. 9640 Medical Center Drive, Rockville, MD 20850

# **AAI 2014 THER5P.830**

